Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Oooooh, That’s Scary! Welcome to the Dark Side of Biopharma

For Halloween, BioSpace collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.

Read More »

Biogen R&D Head Departs for New Role

After multiple failures to develop therapeutics for Alzheimer’s disease, Biogen’s Michael D. Ehlers resigned from his role as head of research and development.

Read More »

Startup Trucode Nabs $34 Million to Support Next-Generation Gene-Editing Technology

Trucode Gene Repair Inc. emerged from stealth mode with $34 million in financing to bolster the biotech startup’s triplex gene-editing technology.

Read More »

Invest with an Option to Buy: Bristol-Myers Squibb Partners with Accelerator BioMotiv

Bristol-Myers Squibb has partnered with biotech accelerator BioMotiv. Bristol-Myers will become a limited partner of BioMotiv, investing in projects of mutual interest, with an option to buy the new companies that are funded and formed once there is a preclinical candidate.

Read More »

Pfizer invests $500 million in expanding gene therapy facility

Pfizer Inc. is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in the company’s efforts to become a major player in gene therapy.

Read More »

New Campaign Focuses on Fighting Superbugs

Leading scientists, public policy experts and biotech industry leaders joined forces to launch “Working to Fight AMR,” a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance.

Read More »

Bayer buys BlueRock in $600 million bet on stem cell therapies

German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics.

Read More »

Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company

Clinical-stage biopharmaceutical company Gemphire Therapeutics Inc. and privately held clinical-stage biotechnology company NeuroBo Pharmaceuticals Inc. jointly announced a definitive agreement whereby NeuroBo will merge with a wholly owned subsidiary of Gemphire in an all-stock transaction.

Read More »

Freenome Secures $160 Million to Advance Cancer Detection Blood Test

Freenome snagged $160 million in Series B financing to support the development of the company’s early cancer detection blood test.

Read More »

Martin Shkreli Loses Criminal Conviction Appeal

Martin Shkreli will continue to reside in federal prison after the notorious “Pharma Bro” failed to win an appeal to his 2017 criminal conviction for securities fraud and conspiracy to commit fraud.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom